2003 OPEN FORUM Abstracts
SURVEY OF CANADIAN HOSPITALS USING THE SENSORMEDICS 3100B HIGH-FREQUENCY OSCILLATORY VENTILATOR: A DESCRIPTIVE STUDY
Catherine Burke-Tremblay RRT, RRCP and Lisa Irvine RRT, Summit Technologies Inc, Oakville, Ontario, Canada, Norman Tiffin RRT, BSc, MSA, Bright's Grove, Ontario, Canada.
Introduction/Background: The SensorMedics 3100B high-frequency oscillator ventilator (VIASYS, Conshohocken, Pa, USA) was approved by the FDA in November 2001 for use in adults and children over 35 kilograms for the treatment of acute respiratory failure. The 3100B High Frequency Oscillatory Ventilator (HFOV) uses rapid, but small volume breaths (typically from 180 to 420 breaths per minute) to remove carbon dioxide while applying higher distending pressures than conventional ventilators to open the lung units and improve oxygen delivery.
Objective: By surveying Canadian hospitals that used the 3100B HFOV within the most recent 12 months we wanted to identify 1) specific adjunctive or supportive therapies, 2) complications arising from this type of ventilator mode and 3) interest in establishing a Canadian users group for 3100B HFOV. We also hoped to identify educational needs these hospitals may require with respect to the use of the 3100B HFOV.
Method: We developed a questionnaire that was administered by using confidential telephone and personal interviews with either the charge respiratory therapist or clinical practice leader for respiratory therapy in 13 tertiary care Canadian hospitals. The survey was performed over a two-month period from May 2003 to July 2003 and based on patients receiving HFOV from May 2002 to May 2003. Responses were collated and evaluated for similarities in adjunctive or supportive therapies and complications while on 3100B HFOV and the need for additional educational support.
Results: We obtained data from 12/13 (92%) of the hospitals that owned oscillators for an average duration of 2 ± 1.6 (mean ± standard deviation) years at the time they were surveyed. Four other hospitals that periodically rent the 3100B HFOV were not included. The adjunctive or supportive therapies practiced in Canadian hospitals using 3100B are shown in Figure 1. The complications that we found in Canadian hospitals using the 3100B HFOV are shown in Figure 2. Of the four sites that experienced inadvertent ventilator disconnect, all reported using lung recruitment maneuvers when reconnecting their patients to the 3100B HFOV. We found that not all Canadian hospitals had current educational material. 100% of respondents favored the development of a Canadian users group for 3100B HFOV.
FIGURE 1 FIGURE 2
Conclusion: Our survey identified that adjunctive supportive therapies are remarkably similar in the hospitals using the 3100B HFOV. We identified four major complications - hypotension, pneumothorax, inadvertent disconnect and obstruction. All hospitals surveyed identified gaps in their current educational material for the 3100B HFOV. Finally, there was a high interest in establishing a Canadian users group for HFOV using 3100B.